On July 26, DexCom (Decans Medical), often referred to as the "little giant" of the U.S. stock market, released its second-quarter (Q2) financial report.The report stated that its revenue increased by 15% from $871.3 million in the second quarter of 2024 to $1 billion.

However, the company's annual revenue forecast left investors "stunned."The company revised its guidance for the full fiscal year, now expecting revenue of $4 billion to $4.05 billion, down from the previous forecast of $4.2 billion to $4.35 billion in the last quarter.Compared with the closing price of the previous day, the company's stock price plummeted in the pre-market trading on July 26, with a decline of up to 38.7%.

"Although Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards," said Kevin Sayer, Chairman, President, and Chief Executive Officer of Decans Medical.

It is reported that Decans Medical is a medical device company, mainly focusing on the design, development, and commercialization of Continuous Glucose Monitoring (CGM) systems for patients, caregivers, and clinicians worldwide to manage diabetes. It is a global leader in the CGM industry.

In 2006, Decans Medical received approval from the U.S. Food and Drug Administration (FDA) to commercialize the company's first product. In 2018, Decans Medical launched a new generation system, the Dexcom G6® Integrated Continuous Glucose Monitoring System (referred to as G6), and in 2023, introduced the Dexcom G7® (referred to as G7).

In March 2024, Decans Medical received FDA approval for the launch of Stelo. Stelo is a new 15-day sensor specifically designed for type 2 diabetes patients who do not use insulin, and it is the first glucose biosensor that does not require a prescription.

In the first half of 2024, Decans Medical's revenue increased by 19% year-on-year to USD 1.925 billion, and its attributable net profit increased by 76% year-on-year to USD 290 million, showing a seemingly good performance.

However, the announcement showed that in the second quarter of 2024, Decans Medical achieved revenue of $1.004 billion, a year-on-year increase of 15%, which was lower than expected; the net profit attributable to shareholders reached $144 million, a year-on-year increase of 24%; the diluted earnings per share in the second quarter were $0.35, compared to $0.28 in the same period last year.

By region, in the second quarter, revenue from the U.S. market was $732 million, a year-on-year increase of 19%, accounting for 73% of total revenue; while revenue from international markets was $272 million, a year-on-year increase of 7%.

Decans Medical also highlighted some strategic achievements in the second quarter in its announcement. For instance, the company launched the "View on Watch" feature in the U.S. and several international markets, offering G7 customers the option to use the Apple (AAPL.US) Watch as the primary display for glucose readings. This feature made the G7 the first and only CGM system capable of connecting to multiple devices simultaneously and directly integrating with the Apple Watch.

In addition, insurance coverage for Dexcom ONE has been secured for type 2 diabetes patients using basal insulin in France, further expanding the reimbursement coverage for real-time CGM in this market.

Despite DexCom's lowered year-end performance forecast, the company reported a 15.7% increase in operating revenue, reaching $158 million. Its revenue in the U.S. grew by 19%, while international revenue increased by 7%.

DexCom also launched a stock repurchase program of up to $750 million, announced simultaneously with its Q2 earnings. The company also reported cash reserves of $31.2 million.

As Decans Medical's main competitor, Abbott raised its full-year earnings forecast last week. Abbott expects diluted earnings per share for the 2024 fiscal year to be between $4.61 and $4.71, compared to the previous quarter’s forecast of $4.55 to $4.70 per share. In addition to Decans Medical, the global continuous glucose monitoring market has also attracted a series of giants actively entering this sector.

Abbott (Abbott)

Abbott provides the FreeStyle Libre series of continuous glucose monitoring systems, directly competing with Decans Medical's products in the market.

Medtronic

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

Optical Giant Enters the Endoscope Market

Samsung Enters the Market, China's AI Imaging Leader

360 Billion, Largest Private Medical Device Company Decans Medical to Go Public

Centennial Medical Device Giant, Billion-Dollar Acquisition

Largest in the World, This Medical Device Giant May Be Up for Sale

Cook Medical Sells Off This Business

Baiyang Pharmaceutical Group Partners with ZAP, a Global Leader in Robotic Radiosurgery

Instrument Giant Acquires Imaging Company

Japanese Equipment Giant's First Layout

Breaking: Cryoablation Leader May Be Delisted

Join【Device Family】WeChat Communication GroupPlease add uniformlyAdministrator WeChat

Please note uniformly: Company + Name/Nickname (Otherwise, it will not be approved.)

BusinessBusiness cooperation email: qxzj@landianyiliao.com